Active Ingredient History
Phenytoin is an anti-epileptic drug. Phenytoin has been used with much clinical success against all types of epileptiform seizures, except petit mal epilepsy. Phenytoin is a available for oral administration (tablets, capsules, suspension). CEREBYX® (fosphenytoin sodium injection) is a prodrug intended for parenteral administration; its active metabolite is phenytoin. CEREBYX should be used only when oral phenytoin administration is not possible. Although several potential targets for phenytoin action have been identified within the CNS (Na-K-ATPase, the GABAA receptor complex, ionotropic glutamate receptors, calcium channels and sigma binding sites) to date, though, the best evidence hinges on the inhibition of voltage-sensitive Na+ channels in the plasma membrane of neurons undergoing seizure activity. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Kidney Injury (Phase 4)
Anemia, Sickle Cell (Phase 2)
Anxiety Disorders (Phase 3)
Asthma (Phase 4)
Astrocytoma (Phase 1)
Automobile Driving (Phase 4)
Bariatric Surgery (Phase 4)
Brain Injuries, Traumatic (Phase 4)
Breast Neoplasms (Phase 1/Phase 2)
Cocaine-Related Disorders (Phase 1)
Cognition Disorders (Phase 4)
Cognitive Dysfunction (Early Phase 1)
Craniocerebral Trauma (Phase 3)
Dementia (Phase 3)
Depression (Phase 4)
Drug Evaluation (Phase 4)
Drug Resistant Epilepsy (Phase 4)
Epilepsy ()
Epilepsy, Post-Traumatic (Phase 3)
Glioblastoma (Phase 1)
Glioma (Phase 4)
Gliosarcoma (Phase 1)
Healthy Volunteers (Phase 3)
Hemoglobinopathies (Phase 2)
HIV Infections (Phase 2)
Leukemia (Phase 1/Phase 2)
Lymphoma (Phase 1/Phase 2)
Meningitis, Pneumococcal (Phase 4)
Multiple Myeloma (Phase 1/Phase 2)
Multiple Sclerosis (Phase 2)
Myelodysplastic Syndromes (Phase 1/Phase 2)
Myeloproliferative Disorders (Phase 1/Phase 2)
Nodding Syndrome (Phase 2)
Non-alcoholic Fatty Liver Disease (Phase 1)
Oligodendroglioma (Phase 1)
Optic Neuritis (Phase 2)
Pain (Phase 1)
Pancreatic Neoplasms (Phase 2)
Pediatrics (Phase 4)
Pharmacokinetics (Phase 4)
Phenytoin (Phase 4)
Polyradiculoneuropathy (Phase 2/Phase 3)
Precancerous Conditions (Phase 1/Phase 2)
Pregnancy (Phase 2)
Psychophysiologic Disorders (Phase 3)
Re-Epithelialization (Phase 2)
Renal Insufficiency (Phase 4)
Sarcoma (Phase 2)
Sarcoma, Ewing (Phase 2)
Schizophrenia (Phase 3)
Seizures ()
Subarachnoid Hemorrhage (Phase 4)
Thalassemia (Phase 2)
Wound Healing (Phase 1)
Wounds and Injuries (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
